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Steroid-refractory chronic graft-versus-host disease (cGVHD) carries a poor prognosis with no agreed upon
algorithm for treatment. Because both B and T cells contribute to the pathophysiology of cGVHD, we con-
ducted a phase I study in subjects with steroid-refractory cGVHD using the anti-CD52 antibody alemtuzumab
to transiently deplete most mononuclear subsets. Three regimens were investigated in a 3þ3 dose-escalation
design: 3 mg  6 (dose level 1), 3 mg  1, then 10 mg  5 (dose level 2) and 3 mg  1, 10 mg  1, then
30 mg  4 (dose level 3) administered over 4 weeks. The maximum tolerated dose of alemtuzumab was dose
level 2. Thirteen patients were assessable for toxicities, which were primarily infectious and hematologic.
Rates of infectious complications in the ﬁrst 12 weeks were 0% at dose level 1 (n ¼ 3), 50% at dose level 2
(1 death, n ¼ 6), and 75% at dose level 3 (2 deaths, n ¼ 4). Of 10 patients assessable for response, 7 (70%)
responded at 12 weeks, with a 30% complete response rate. Four subjects reduced steroid dose or dis-
continued an immunosuppressant at 12 weeks. The median decrease in steroid dose at 1 year was 61.6%.
Infectious complications occurred predominantly in the ﬁrst 3 months after therapy, but full B and T cell
recovery took well over 12 months. Immunophenotypic proﬁling revealed early recovery by natural killer
cells and relative sparing of CD4þ and CD8þ central memory T cell subsets. Our study indicates that therapy
with alemtuzumab for steroid-refractory cGVHD is tolerable with close attention to dosing and may be active
in subjects who have failed multiple therapies. The pattern of lymphocyte recovery after alemtuzumab will
inform the biology and future therapy of cGVHD. The use of alemtuzumab in the context of therapy for cGVHD
deserves study in larger phase II trials.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
For patients undergoing allogeneic hematopoietic stem
cell transplantation (HSCT) who survive the peri-
transplantation period and evade relapse of their neoplasm,
chronic graft-versus-host disease (cGVHD) is a major cause
of morbidity and mortality. cGVHD and infections associated
with the underlying immune dysregulation and attendant
immune suppressive treatments are the cause of death in
more than 15% of HSCT recipients, making it the leading
cause of late treatment-relatedmortality [1,2]. Multiple trials
of second-line treatment options have failed to identify an
extremely effective or long-lasting treatment modality for
patients who are refractory to ﬁrst-line steroid therapy [3,4].
It is generally accepted that donor T cells play a central
role in the development of both acute (aGVHD) and cGVHD,
with most studies of in vivo or ex vivo T cell depletion of the
HSCT product demonstrating decreased incidence of GVHD
in recipients [5]. However, the contributions of other types of
immune cells are being recognized, namely, autoreactive B
cells, dendritic cells, and natural killer (NK) T cells [6]. This
recognition has led to therapeutic trials of agents affecting
lymphocytes other than T cells, such as rituximab, andedgments on page 810.
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[7,8].
Alemtuzumab, also known as Campath-1H, is a human-
ized IgG1 monoclonal antibody that binds to human CD52,
an antigen present on most human mononuclear subsets (B,
T, and NK cell lymphocytes, monocytes, macrophages,
monocyte-derived dendritic cells, and eosinophils) but not
on hematopoietic stem cells [9]. It is used in treatment of
chronic lymphocytic leukemia, various T cell malignancies,
and autoimmune conditions such as vasculitis and multiple
sclerosis. When included as part of pre-HSCT conditioning,
alemtuzumab is reported to decrease the incidence of
aGVHD and cGVHD without compromising engraftment
[10,11]. This improvement in GVHD is accompanied by
increased rates of relapse and infectious complications,
particularly cytomegalovirus (CMV) reactivation and disease,
with similar rates of survival as those seen in recipients of
T cellereplete transplantations [5].
Alemtuzumab has been used as experimental therapy for
steroid-refractory aGVHD with response rates ranging from
50% to 94% and complete response rates of 20% to 35%
[12-15]. Until recently, the only publications on use of
alemtuzumab in steroid-refractory cGVHD were case reports
of patients with cutaneous and noninfectious pulmonary
manifestations and 1 recent trial where it was given in
combinationwith rituximab [16-18]. Because of the potential
for signiﬁcant infectious complications and the wide varia-
tion in doses and outcomes described in prior studies usingTransplantation.
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dosing was needed. This is the ﬁrst prospective, phase I,
dose-escalation study to assess the addition of alemtuzumab
alone to standard treatment of steroid-refractory cGVHD.METHODS
Patient Characteristics
Between June 2007 and August 2011, 13 subjects were enrolled on this
open-label, phase I dose-escalation trial. The primary objective was to
determine the maximum tolerated dose (MTD) and toxicity of alemtuzumab
in subjects with steroid-refractory cGVHD. The secondary objective was to
determine efﬁcacy. The protocol was approved by the Human Subjects
Committee of the Dana-Farber Cancer Institute/Harvard Cancer Center Insti-
tutional ReviewBoard and registered at ClinicalTrials.gov (NCT00495755). All
participants provided written informed consent at the time of enrollment.
Alemtuzumab was initially supplied by Genzyme (Cambridge, MA).
Eligible subjects had cGVHD at the time of enrollment that was currently
or had been resistant or refractory to steroid therapy equivalent to predni-
sone at .5 mg/kg/day for at least 4 weeks in the preceding 12 months.
cGVHD and grading severity was deﬁned as per National Institutes of Health
(NIH) consensus criteria [19]. Doses of corticosteroids and other immuno-
suppressants had to remain unchanged for 4 weeks before enrollment.
Therapy with corticosteroids at trial initiation was not a requirement.
Individuals were permitted to initiate organ-speciﬁc topical therapy
throughout the trial period. Individuals who had undergone ablative or
reduced-intensity conditioning before receiving donor cells from any source
at least 180 days before registration were eligible. Adequate bone marrow
function as indicated by an absolute neutrophil count >1000/mL and
platelets >50,000/mL at enrollment was required. Notable exclusion criteria
were prednisone requirements of 2 mg/kg/day, uncontrolled infection,
active relapse of malignant disease, or HIV seropositivity.
All subjects were restarted or maintained on prophylactic antimicrobials
against Pneumocystis jirovecii, herpes virus, and varicella virus. All subjects
were required to use antifungal prophylaxis for 6 months after initiation of
alemtuzumab therapy. CMV viral load by hybrid capture assay or poly-
merase chain reaction was performed, along with weekly blood work and
physicals, during weeks 1 to 6 and then on weeks 8, 10 and 12. Pre-emptive
therapy with valganciclovir or ganciclovir was initiated for positive CMV
assays.Study Design and Deﬁnitions
Alemtuzumab was administered as an intravenous formulation at
30 mg/100 mL in .9% sodium chloride. Premedication consisting of
diphenhydramine and acetaminophen was administered before the ﬁrst
dose, at dose escalations, and as clinically indicated. Intravenous cortico-
steroids were not administered before alemtuzumab and were given
subsequently only for evidence of an infusional reaction.
The schedule for alemtuzumab was 3 times a week for 1 week, followed
byweekly infusions for 3 additional weeks, for a total of 6 doses (days 1, 3, 5,
8, 15, and 22). Three dose levels were investigated in a standard 3þ3 dose-
escalation design: 3 mg  6 (dose level 1), 3 mg  1, then 10 mg  5 (dose
level 2) and 3 mg  1, 10 mg  1, then 30 mg  4 (dose level 3). Physicians
were encouraged to maintain immunosuppressive medications and
constant doses until 12 weeks had elapsed to evaluate in isolation the
impact of alemtuzumab, unless deterioration in clinical status or drug levels
outside the therapeutic range dictated otherwise. Schedule or response
criteria for tapering of steroids and other immunosuppressants at and after
the 12 week end-of-study evaluation were not speciﬁed but were at the
discretion of the treating physician. Dose-limiting toxicities (using the
Cancer Institute’s Common Terminology Criteria for Adverse Events, version
3.0 [http://ctep.cancer.gov/protocoldevelopment/electronic_applications/
docs/ctcaev3.pdf]) were deﬁned as anaphylaxis secondary to alemtuzumab
infusion, grade 4 hematologic toxicity or nonhematologic toxicity directly
related to alemtuzumab, and grade 4 infectious complications observed
within the ﬁrst 12 weeks of initiating therapy. Subjects were followed for
adverse events for at least 12 months with attribution based on clinical
assessment.
At the time of enrollment and 12 weeks after initiation of therapy,
assessment of cGVHD severity using the NIH consensus criteria was
undertaken by the treating physician, including organ-speciﬁc scores and
global severity scores. A complete response was deﬁned as resolution of all
reversible cGVHD-associated manifestations. A partial responsewas deﬁned
as a decrease of 1 point or more on a 3-point organ-speciﬁc scale or 2 points
or more on a 10-point physician-determined global severity scale, without
progression at other organs or sites [20]. Stable disease was deﬁned as no
change in the organ-speciﬁc scores and a change by only 1 point in either
direction on a 10-point physician-determined global severity score.Progressive disease was deﬁned as any increase on a 3-point organ-speciﬁc
scale, a 2-point or greater increase in the subjective global severity scale, or
the need to increase steroid dose or other immunosuppressant therapy as
determined by the treating clinician. Sites of ocular or oral cGVHD were not
scored for response because changes in topical therapy were permitted
during the study and were likely to inﬂuence organ-speciﬁc outcomes.
Stabilization of pulmonary cGVHD is a partial response according to NIH
criteria, but improvement was required to meet partial response in this
study. Failure-free survival was deﬁned as absence of additional therapy,
nonrelapse mortality, or malignant relapse [21]. Subjects with a clinical
beneﬁt could elect to receive a second course of alemtuzumab therapy on
the same dosing schedule.
Laboratory and Statistical Analysis
Protocol-speciﬁed immunophenotypic analyses were performed at
baseline and monthly as subject status permitted, up to at least 1 year after
therapy. Fifty microliters of whole blood (15% EDTA) was incubated with
ﬂuorophore-conjugated monoclonal antibodies: anti-CD3 V450 (clone
UCHT1, BD Biosciences), anti-CD4 APC-H7 (clone RPA-T4, BD Biosciences),
anti-CD8 Paciﬁc Orange (clone 3B5, Invitrogen, Carlsbad, CA), anti-CD25 PE-
Cy7 (clone M-A251, BD Biosciences, San Jose, CA), anti-CD127 PE-Cy5 (clone
eBioRDR5, eBioscience), anti-CD56 PE (clone B159, BD Biosciences), anti-
CD20 APC-H7 (clone 2H7, BD Biosciences), anti-CD45RO FITC (clone UCHL1,
BD Biosciences, San Diego, CA), anti-CD62LAPC (clone Dreg 56, BD Biosci-
ences), CD11cþ PE-Cy5 (clone B-ly6, BD Biosciences), and CD123 FITC (clone
AC145, Miltenyi, Cambridge, MA). Red cell lysis with 500 mL of BD PharmLyse
solution followed. Cell analysiswas performed using the FACSCanto II system
(BD Biosciences) and FACSDiva software (BD Biosciences). Regulatory T cells
were deﬁned as CD3þCD4þCD25med-highCD127low, conventional Tcells as
CD3þCD4þCD25neg-lowCD127med-high, NK cells as CD3-CD56þ, B cells as
CD20þ, myeloid dendritic cells as HLA-DRþCD11cþ, and plasmacytoid
dendritic cells as HLA-DRþCD123þ. Naive T cells were deﬁned as CD45RO-
CD62Lþ, terminal effectors as CD45RO-CD62L-, central memory as
CD45ROþCD62Lþ, and effector memory as CD45ROþCD62L.
Subject baseline characteristics are reported descriptively. Because of
the small sample size, statistical associations were not tested. Overall
survival was deﬁned as the time from trial initiation to death from any
cause, and surviving subjects were censored at their date of last known
follow-up. Survival estimates were calculated using the method of Kaplan
and Meier [22].
RESULTS
Subjects
Thirteen subjects were enrolled; all were assessable for
toxicity. Median follow-up time among survivors was 42.8
months (range, 17.9 to 59.4). Median age of subjects was 55
years (range, 35 to 67) (Table 1). Median time from cGVHD
diagnosis to trial study enrollment was 21.1 months (range,
1.1 to 55.8). Six subjects had moderate and 7 subjects had
severe cGVHD per NIH consensus global scoring criteria; all
had “extensive” disease [23]. Median number of organ sites
involved by cGVHD was 4 (range, 1 to 7). Skin and subcuta-
neous tissues were involved in all subjects.
Subjects had been on a median of 5 forms of systemic
immune suppression, including steroids (range, 2 to 7 agents
total), before trial initiation. Several subjects had been
treated with other experimental agents previously, including
rituximab, low-dose interleukin 2, and alefacept (Table S1).
At trial initiation, subjects were on a median of 2 (range, 1 to
3) systemic immunosuppressants in addition to steroids.
These were primarily a calcineurin inhibitor (CNI), sirolimus,
and mycophenolate mofetil, doses of which had all been
stable for 4 weeks before trial initiation (see Methods for
eligibility; Table S1). The median dose of prednisone at trial
initiation was 30 mg daily (range, 0 to 80 mg; .42 mg/kg,
range, 0 to 1.12 mg/kg). No subject had undergone donor
lymphocyte infusion.
Fourteen courses of alemtuzumab were given to the 13
subjects on study, all in the ambulatory clinic setting. Two
subjects underwent later retreatment with alemtuzumab
outside the study period. Three subjects were treated at dose
level 1, 6 subjects at dose level 2, and 4 subjects at dose level 3.
Table 1
Demographics
Characteristic Value
Subjects enrolled, n 13
Subjects evaluable for safety, n 13
Subjects evaluable for efﬁcacy, n 10
Male gender, n (%) 8 (61.5)
Median age, yr (range) 55 (35-67)
Stem cell donor, n (%)
HLA-matched sibling 3 (23)
HLA-matched unrelated 7 (54)
7/8 HLA-matched unrelated 3 (23)
Stem cell source, n (%)
Peripheral blood stem cells 13 (100)
Conditioning regimen
Myeloablative 6 (46)
Nonmyeloablative 7 (54)
Acute GVHD prophylaxis, n (%)
Tacrolimus - methotrexate 1 (7.7)
Tacrolimus - rapamycin 3 (23)
Tacrolimus - rapamycin - methotrexate 7 (54)
Tacrolimus - methotrexate - bortezomib 1 (7.7)
Cyclosporin - methotrexate 1 (7.7)
Prior acute GVHD, n (%)
Grades 0-I 11 (84.6)
Grades II-IV 2 (15.4)
CMV status (donor/subject), n
þ/þ 4 (31)
þ/ 0
/þ 4 (31)
/ 5 (38)
Median time post-HSCT, mo (range) 26.3 (8.3-63.6)
Median time post-cGVHD Onset, mo (range) 21.1 (1.1-55.8)
NIH consensus cGVHD severity grade, n
Mild 0
Moderate 6
Severe 7
Median cGVHD sites per subject, n (range) 4 (1-7)
Skin/subcutaneous (SC) tissue (no. subjects) 13
Eye 9
Liver 9
Mouth 8
Joint/fascia/muscle (J/F/M) 7
Gastrointestinal tract (GI) 3
Lung 2
Median cGVHD agents - current or prior, n (range) 5 (2-7)
Systemic steroids (no. subjects) 13
Calcineurin inhibitors (CNI) 11
Mycophenolate mofetil (MMF) 10
Sirolimus 10
Rituximab 6
Extracorporeal photopheresis (ECP) 4
Imatinib 3
Interleukin 2 2
Alefacept 1
6-Mercaptopurine 1
Median prednisone dose at enrollment,
mg/kg (range)
0.42 (0-1.12)
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TheMTDwas dose level 2. Twoof 4 subjects at dose level 3
experienced dose-limiting toxicities. One died of non-
neutropenic Escherichia coli bacteremia on day 8; a second
had grade 4 neutropenia/thrombocytopenia and died of
Corynebacterium bacteremia at week 11. One subject at dose
level 2 experienced a dose-limiting toxicity of grade 4 neu-
tropenia/thrombocytopenia and died of adenoviral pulmo-
nary infection at week 6 after alemtuzumab initiation.
Toxicities of Common Terminology Criteria for Adverse
Events grade 3 or higher were primarily infectious or hema-
tologic (Table 2). The only noninfectious and nonhematologic
toxicitywas grade 3 thromboticmicroangiopathy, in a subject
on supratherapeutic doses of tacrolimus.Percentages of subjects with infectious complications in
the ﬁrst 12 weeks, excluding herpes simplex virus (HSV) and
cytomegalovirus (CMV) reactivations, were 0% at dose level 1
(n ¼ 3), 50% at dose level 2 (1 death, n ¼ 6), and 75% at dose
level 3 (2 deaths, n ¼ 4) (Table 2). Viral infections were
primarily pneumonias due to parainﬂuenza, inﬂuenza, and
adenovirus. Identiﬁed bacterial pathogens included E. coli,
Pseudomonas, and Corynebacterium manifesting as pneu-
monia, bacteremia, and an abscess. Herpes simplex virus
reactivations were conﬁned to oral mucosa. There were 4
episodes of CMV reactivation (30.8%). Only 1 subject expe-
rienced persistent CMV reactivation despite preemptive
therapy with ganciclovir. There were no cases of clinically
evident CMV disease.
Between 12 and 24 weeks of the trial, the rate of infec-
tious complications was dramatically reduced. One subject at
dose level 3 developed BK viremia and cystitis at week 14
and subsequently developed an Escherichia coli epididymo-
orchitis. Two subjects experienced reactivation of CMV; 1
of these subjects also reactivated Epstein-Barr virus. CMV
and Epstein-Barr virus viremias were responsive to pre-
emptive therapy with ganciclovir or rituximab, respec-
tively. In long-term follow-up from 24 weeks to 1 year after
completion of therapy, there were no subsequent viral
reactivations. Four subjects experienced non-neutropenic
bacterial pneumonias (Haemophilus inﬂuenza, Klebsiella
pneumoniae) at 6 months or later that were considered
unlikely to be related to alemtuzumab therapy. The 1 death
occurring between 12 weeks and 1 year after alemtuzumab
therapy was of a subject at dose level 1 who presented 4
months after a second course of alemtuzumab with
a pulmonary infection from both E. coli and Aspergillus
(Table S2).
Hematologic toxicity of grade 3 or higher in the ﬁrst 12
weeks was seen in 2 subjects at dose level 3 and 1 subject at
dose level 2 (Table 2). Two of 3 deaths in the ﬁrst 12 weeks
were in the setting of grade 4 neutropenia. However, most
infectious complications in the ﬁrst 12 weeks and later were
seen in subjects who were not neutropenic. Grade 3 neu-
tropeniawas seen in 1 subject at dose level 3, lasting 6 weeks
and requiring granulocyte colony-stimulating factor admin-
istration. Over the 80 doses of alemtuzumab given to the 13
subjects, 9 grade II infusional reactions were seen. No
interventions besides 50 mg methylprednisolone or 100 mg
hydrocortisone i.v., ranitidine, diphenhydramine, and/or
meperidine were needed. In 8 cases, the infusion was then
completed without event. Seven events were seen at a dose
of 3 mg and the other 2 at a dose of 10 mg; all occurred
within the ﬁrst 3 infusions.
With a median follow-up of over 3 years, 2 other medical
events were noted, of unclear relationship to alemtuzumab
therapy. Eighteen months after completion of study and
discontinuation of all immunosuppressive medications, 1
subject at dose level 2 developed immune thrombocytopenia
and nephrotic syndrome with collapsing glomerular scle-
rosis. Both conditions were treated successfully with a pro-
longed steroid taper. Three years after completion of therapy,
a second subject at dose level 2 was noted to have a cervical
extensor myopathy and sensorimotor polyneuropathy of
unclear etiology (Table S2).
Efﬁcacy
Ten of 13 subjects were alive and assessable for response
at week 12. Three subjects had complete responses, 4 had
partial responses, 2 had stable disease, and 1 had cGVHD
Table 2
Responses and Toxicities
A. Week 12 Weeks 1-12
Cohort cGvHD Response Viral Reactivation Viral Infection Bacterial Infection Hematologic
1 Partial d d d d
1 Partial d d d d
1 Partial CMV - Wk 3 d d d
2 Complete Oral HSV - Wk 12 d d d
2 Complete d d d d
2 Stable d Grade 3 parainﬂuenza - Wk 4
Grade 3 inﬂuenza A - Wk 11
Grade 3 pseudomonas pneumonia - Wk 11 d
2 Progression d d d d
2 Complete Oral HSV - Wk 9 d Grade 3 perirectal abscess - Wk 12 d
2 Deceased CMV - Wks 3þ6 Grade3 BK - Wk 6
Grade 5 adenovirus - Wk 6
Grade 3 Fevers with presumed bacterial
infection - Wk 3
Grade 4 NþT - Wk 6
3 Partial Oral HSV - Wk 2
CMV - Wk 4
d d d
3 Deceased d d Grade 5 E. coli bacteremia - Wk 2 d
3 Stable CMV - Wks 4-6 Grade 3 parainﬂuenza - Wk 9 d Grade 3 N - Wk 9
Grade 3 TMA - Wk 9
3 Deceased d d Grade 3 dental abscess - Wk 4
Grade 5 corynebacterium bacteremia - Wk 9
Grade 4 NþT - Wk 9
N indicates neutropenia; T, thrombocytopenia; TMA, thrombotic microangiopathy; Wk, week.
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10-point global severity score (Tables 2 and 3; see Methods
for deﬁnition of response). All 3 subjects at dose level 1 had
partial responses. The complete responses were all seen at
dose level 2. The sole subject with progressive disease (dose
level 2) met the deﬁnition of stable disease (ie, no change in
organ-speciﬁc scores and a change of only 1 point in the
global severity score). However, given the impression of mild
worsening of sclerodermatous changes, steroids were
increased and an additional immunosuppressive agent was
started at the week 12 visit. When scored according to NIH
consensus criteria, 3 of 6 subjects with initially moderate
disease converted to mild and 2 of 4 subjects with initially
severe disease converted to moderate disease. The 3 subjects
in the mild NIH consensus category at week 12 had residual
symptoms of grade 1 eye and/or mouth involvement.Table 3
Clinically Relevant Outcomes
Variable at 12 Weeks Dose
Level 1
Dose
Level 2
Dose
Level 3
Total
Number evaluable 3 5 2 10
cGVHD response, n*
Complete response 3 3
Partial response 3 1 4
Stable disease 1 1 2
Progression 1 1
NIH consensus cGVHD severity
Grade, ny
Mild 3 3
Moderate 3 1 1 5
Severe 1 1 2
Sites of response, no. events
Skin/SC tissue 1 2 1 4
JFM 1 1 1 3
GI 1 2 3
Liver 1 1
Lung 1 1
Steroid dose at 12 months
None 2 2
Ongoing but decreased 1 3 1 5
Unchanged 1 1
Increased 1 1
Median % change in steroid
dose (mg/kg) since initiation
61.64%
* See Methods for full description of response criteria.
y Deﬁned by cGVHD NIH Consensus Guidelines.Organs of response were primarily skin and joint/fascia/
muscle tissues, but improvements were also seen in gastro-
intestinal symptoms (dysphagia), liver abnormalities (1
subject), and pulmonary manifestations (1 subject) (Table 3).
Of 7 subjects manifesting complete or partial responses, 5
reported softening of skin and/or improved joint mobility
within 1 to 3 weeks of starting therapy. Although not
included in our response criteria, ocular and oral involve-
ment in all subjects was either stable or improved.
At the end-of-trial 12-week visit, 3 subjects (2 with
complete responses and 1 with stable disease) decreased
steroid doses, and 1 subject with a partial response discon-
tinued a concurrent immunosuppressant. At 1 year, median
percent decrease in steroid dose since study initiation in all
surviving subjects was 61.6% (Table 3). Steroid doses
decreasedby53% to100% for subjects at dose level 2, theMTD.
One year after trial completion, 2 of 9 assessable subjects
remained off steroids and 4 others were on prednisone doses
of 7.5 mg/day or less. Five subjects had added no new
immunosuppressive agents since trial initiation and were on
0 to 1 immunosuppressants at last interval visit (Table S2).
Three subjects received a second course of alemtuzumab,
Median failure-free survival for all subjects was 8.5
months, and failure-free survival at 1, 2, and 3 years was
30.8%, 23.1%, and 23.1%, respectively (see Methods for deﬁ-
nition). The median survival from alemtuzumab was 44.7
months, with overall survival at 2 years and 3 years of 69.2%
and 59.3%, respectively (Figure 1). No patient relapsed afterFigure 1. Kaplan-Meier curve: probability of survival versus months after
alemtuzumab administration.
Figure 2. Leukocyte and lymphocyte recovery after alemtuzumab administration. (A) Median total white blood cell (solid line) and leukocyte (dashed line) numbers
for all assessable subjects at indicated time points. (B) Repopulation of lymphocyte subsets as reﬂected by median CD3þ T cell, CD20þ B cell, and CD56þCD3-NK cell
concentrations among all assessable subjects at indicated time points.
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chimerism.
Immunologic Effects
One month after dosing of alemtuzumab at all 3 dose
levels, median decrease in white blood cell was 37.2% (range,
92.1% decrease to 6.8% increase). There was recovery to
baselinewhite blood cell by 1 year in all subjects, with longer
delay in recovery seen as alemtuzumab doses increased
(Figure 2A and data not shown). Granulocyte counts showed
a great variation in response at 1 month (range, 92.8%
decrease to 245% increase), whereas monocyte and
lymphocyte counts dropped in all subjects to almost unde-
tectable. All 9 subjects surviving past 1 year recovered
baseline monocyte counts, with a median time to recovery of7.5 months (range, 2 to 18 months). Lymphocyte counts
started to rebound by 3 to 9 months. Only 2 subjects recov-
ered lymphocyte counts back to a pretreatment baseline by
1 year (Figure 2A and data not shown).
For most individuals, most lymphocytes present for the
ﬁrst year were CD56þ CD3-NK cells (Figure 2B). In only 4
subjects did T cell numbers return to pretherapy baseline at
any time during the follow-up period; in those subjects,
median time to recovery was 18 months (range, 9 to
30 months), regardless of alemtuzumab dose level. No
preferential sparing of either CD4þ or CD8þ T cells was
observed (Figure 3A). Neither initial preferential sparing nor
a subsequent homeostatic expansion of CD25þ CD127low
regulatory T cells was consistently detected (Figure 3B). Six
subjects recovered their B cell counts within the follow-up
Figure 3. T cell subset composition after alemtuzumab administration. (A) Normalized median CD4 and CD8 T cell percentages within the CD3þ T cell population
among all assessable subjects. (B) Normalized median conventional T cells “Tcon” (CD3þCD4þCD25neg-lowCD127med-high) and regulatory T cells “Treg”
(CD3þCD4þCD25med-highCD127low) percentages within the CD4þ T cell subset among all assessable subjects. (C and D) Normalized median percentages of
CD45ROþCD62Le effector memory cells, CD45ROþCD62Lþ central memory cells, CD45RO-CD62Le terminal effector cells, and CD45RO-CD62Lþ naive cells in the
CD4þ (C) and CD8þ (D) T cell subsets among all assessable subjects.
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was no detectable trend between response, infections, or
survival post-treatment and recovery of B or T cells within 12
months.
The most consistent immunophenotypic changes were in
the distribution of CD4þ and CD8þ T cells between memory
and effector phenotypes. The CD4þ population of subjects
before therapy was variably distributed with no clearly
dominant subset. After alemtuzumab initiation, there was
preferential sparing of the CD4þ central memory subset and
virtual elimination of naive cells and terminal effectors in
almost all subjects (Figure 3C). Over time, effector memory
cells repopulated as the dominant subgroup. Preferential
sparing of central memory cells was also seen initially in the
CD8þ T cell subset after initiation of alemtuzumab with
reconstitution of a dominant population of terminal effectors
CD8þ T cells over time (Figure 3D). There was no observed
correlation between a particular distribution pattern of
CD4þ or CD8þ T cell effector/memory phenotypes and
clinical infections or response. In all 10 assessable subjects,
CD11cþ myeloid dendritic cells seemed to be preferentially
spared and predominated over CD123þ plasmacytoid
dendritic cells throughout the follow-up period, with
a median of 65.8% myeloid versus 8.2% plasmacytoiddendritic cells within the HLA-DRþ population at 12 months
(data not shown) [24].
DISCUSSION
Safety and Efﬁcacy
Although HSCT recipients with ensuing mild cGVHD have
similar if not improved overall survival as compared with
recipients without GVHD, the onset of moderate to severe
cGVHD has a profound impact on nonrelapse mortality and
overall survival [1]. Recognizing potential roles for lympho-
cyte subsets such as B cells, NK cells, and dendritic cells in the
pathogenesis of cGVHD, we used alemtuzumab in a phase I
trial to treat 13 subjects with moderate to severe steroid-
refractory cGVHD who had been failed by multiple other
treatment modalities. Based on requirements for stability of
immunosuppressant dose on initiation, subjects enrolled
were primarily those with cGVHD that was clinically stable
but with suboptimal responses and signiﬁcant morbidity on
their current/prior therapies, those with a recent clinical
change for which increased doses of steroids or addition of
another immunosuppressive agent was foregone in favor of
initiation on study, and not those subjects whose diseasewas
dramatically worsening or progressively improving on
current therapies.
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to be dose level 2: 3 mg on day 1 and then 10mg on days 3, 5,
8, 15, and 22. Efﬁcacy was the highest at dose level 2. Infec-
tious complications, excluding viral reactivation, were seen
in 46.2% of subjects overall, with the incidence and severity
of infections increasing with alemtuzumab dose. In our
study, infectious complications were primarily bacterial in
nature and peaked relatively early, in the ﬁrst 12 weeks after
therapy. Despite the underlying immune dysregulation that
characterizes cGVHD and high doses of immunosuppressants
in these subjects, CMV reactivation (30.8%), Epstein-Barr
virus reactivation (7.7%), BK virus (15.4%), and fungal infec-
tion (7.7%) rates were relatively low and occurred within 4
months of therapy. These kinetics are consistent with those
described previously; in patients undergoing conditioning
with alemtuzumab, mean time of reactivation of CMV is 24
days with reconstitution of CMV-reactive cytotoxic T
lymphocytes seen by day 90 [25,26]. Antiviral and antifungal
prophylaxis and aggressive monitoring for CMV reactivation
with pre-emptive therapy as performed in this trial are
highly recommended.
At the prespeciﬁed study endpoint of 12 weeks, there was
a response rate of 70% and a complete response rate of 30%
based on our grading scheme. One-half of the assessable
subjects downgraded their GVHD severity based on NIH
consensus criteria. Four of 10 subjects were able to decrease
their steroid doses or discontinue an immunosuppressive
medication at the 12 week end-of-trial visit. Five of 9
subjects were on minimal immunosuppression at 1 year.
These results are comparable with those in other accepted
and experimental secondary therapies for cGVHD, including
photopheresis, imatinib, mycophenolate, alefacept, ritux-
imab, and inﬂiximab, for which response rates have ranged
from 20% to 86% with wide variation in deﬁnitions of
response, complete response rates, and overall survival [27].
There were no relapses among our study participants, and
our overall survival was similar to historical control subjects
with cGVHD [23].
When combined with studies of aGVHD and a publication
of alemtuzumab in concert with rituximab for cGVHD, our
study adds to the body of literature suggesting alemtuzumab
is an effective agent in GVHD, with response rates of 50% to
100% and complete response rates of 20% to 35% [12-18,28].
However, the signiﬁcant incidence of infectious complica-
tions, which in our study at the MTD are perhaps less
frequent than in the literature, emphasizes the importance of
subject selection, dosing schedule of alemtuzumab, and
rigorous antiviral and antifungal prophylaxis.
Immunologic Effects
One novel aspect of our study is documentation of the
long-term effects of alemtuzumab on lymphocyte subsets in
subjects with cGVHD, albeit in a limited number of subjects
on multiple immunosuppressants. In scenarios as varied as
multiple sclerosis, rheumatoid arthritis, and conditioning for
solid organ and stem cell transplantation, T cell lymphopenia
after alemtuzumab is known to be long-lasting [29]. Median
complete recovery times are often over 1 year, and up to 30%
of patients may never recover baseline T cell numbers, even
after a decade. After therapy in autoimmune diseases, long-
term changes in B cell subsets, shifts within CD4þ T cell
subsets, and preferential sparing or expansion of regulatory
T cells have been described [30-32].
Our data similarly revealed a profound and prolonged,
quantitative decrease in the CD3þ T cell population ofsubjects with cGVHD. We found an initial sparing of central
memory cells, whereas effector memory cells eventually
repopulated in both the CD4þ and CD8þ populations. The
preferential recovery of memory T cells likely reﬂects
persistent thymic injury resulting in an inability to generate
naive T cells. The lack of naive cells and preferential expan-
sion of memory T cells is likely associated with a markedly
reduced T cell repertoire, further contributing to suscepti-
bility to viral and fungal infections. However, signiﬁcant
variations occurred between individuals as to the kinetics
and distribution of T cell subsets upon repopulation. In our
small study, no ﬁrm correlations with clinical outcome could
be made.
Depletion of NK cells was less profound than depletion of
other lymphocytes, and NK cells were the ﬁrst immune
population to recover. Despite a profound effect on B cells,
a higher fraction of subjects were able to regain baseline
numbers of B cells than T cells and did so with faster kinetics.
The different degrees of depletion and timing of recovery
could indicate a lower expression level of CD52 on NK and B
cells and/or less reliance by these populations during their
reconstitution on a thymus rendered dysfunctional by age,
chemotherapy, allogeneic HSCT, and cGVHD. We could
postulate that the more rapid recovery of NK cells and
normalization of the effector-to-central memory cell ratio
therapy (despite T cell lymphopenia) contributed to the
reduction in infections seen by 3 to 4 months after alemtu-
zumab. Larger trials of alemtuzumab in cGVHD should
include correlative studies of serologic markers (eg,
interleukin-21 and B cell activating factor/BAFF) as well as
long-term immunophenotyping and functional proﬁling of
regulatory and effector/memory Tcell subsets, NK cells, and B
cell subsets to highlight mechanisms of ameliorating GVHD
that can be exploited bymore targeted therapies in the future.
In summary, alemtuzumab is emerging in both the
aGVHD and cGVHD settings as a viable therapeutic option for
steroid-refractory disease. Infectious complications are
signiﬁcant but largely conﬁned to the early period after
alemtuzumab administration in cGVHD. We provide in this
prospective analysis a formal dose escalation of intravenous
alemtuzumab and identify a maximum-tolerated schedule
with good short-term response rates, long-term decreases in
steroid use, and acceptable rates of infectious complications
in subjects treated in an outpatient clinic setting. Our
description of the relative sparing and reconstitution kinetics
among NK cells, B cells, and naive, effector, and memory T
cell subsets after alemtuzumab in subjects with cGVHD is
novel and hypothesis-generating. Larger studies conﬁrming
efﬁcacy and correlating immunophenotypic changes with
response may advance alemtuzumab into the armamen-
tarium of treatment options and yield insight into the
complex cellular interactions underlying chronic GVHD.
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